Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to tre...
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical ...
Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial
Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations Planned for emergency use as a stockpiled vaccine PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), together with CEPI, ...
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, May 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (NASDAQ: INO) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to res...
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
PLYMOUTH MEETING, Pennsylvania and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (NASDAQ: INO) and Plumbline Life Sciences (XKRX: 222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vaccine...
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
PLYMOUTH MEETING, Pennsylvania, May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal Product Certificate for quality and non-clinical data. The procedure of certifi...
Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development
PLYMOUTH MEETING, Pennsylvania, April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457 (formerly called INO-3112) in ...
Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study
PLYMOUTH MEETING, Pennsylvania, April 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (...
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model PLYMOUTH MEETING, Pennsylvania, April 2, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company's novel DNA-Encoded Bi-specific T Cell Engagers (dBiTEs™) generat...
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
PLYMOUTH MEETING, Pennsylvania, April 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) has completed its enrollment three months ahead of schedule. The 52-patient trial ...
Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases
PLYMOUTH MEETING, Pa., March 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals,
Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe,
tolerable, and generated strong T cell and antibody responses. This Phase 1
data was published inThe Journal of Infectious Diseases
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
The second Phase 3 study initiation announcement made during the International HPV Awareness Day PLYMOUTH MEETING, Pennsylvania, March 4, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the initiation and opening of sites to enroll the second portion of the compan...
Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor
PLYMOUTH MEETING, Pennsylvania, Jan. 24, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remissio...
Inovio's dMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies
PD-1 DNA-encoded monoclonal antibodies (dMAbs) highlighted in a paper published in cancer journalOncotarget PLYMOUTH MEETING, Pennsylvania, Jan. 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the successful development of optimized DNA-encoded monoclonal ant...
Inovio's DNA-Encoded Monoclonal Antibody (dMAb(TM)) Platform Leaps Forward with First-in-Human Trial
PLYMOUTH MEETING, Pennsylvania, Jan. 7, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) in collaboration with The Wistar Institute and theUniversity of Pennsylvania announced today the initiation of the first human study of its DNA-encoded monoclonal antibody (dMAb™) technology to...
